EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSECRG00000000795
Gene Symbol: MAP3K11
3 Cross references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12-Like

Ensembl ID : ENSECRG00000004705
Gene Symbol: LOC114649075
3 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSECRG00000018087
Gene Symbol: MAP3K13
3 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSECRG00000001323
Gene Symbol: MAP3K5
3 Cross references
209 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSECRG00000014680
Gene Symbol: MAP3K8
3 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSECRG00000016016
Gene Symbol: MAP3K9
3 Cross references
196 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSECRG00000018082
Gene Symbol: MGLL
3 Cross references
209 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSECRG00000013160
Gene Symbol: NPR2
3 Cross references
260 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSECRG00000014031
Gene Symbol: NPR3
3 Cross references
211 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 2-Like

Ensembl ID : ENSECRG00000022132
Gene Symbol: LOC114667713
3 Cross references
196 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-4-Like

Ensembl ID : ENSECRG00000006928
Gene Symbol: LOC114659747
3 Cross references
206 Possible Orthologues:

Neuropeptide Y Receptor Y2, Like

Ensembl ID : ENSECRG00000021952
Gene Symbol: NPY2RL
1 Cross references
248 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).